Skip to search formSkip to main contentSkip to account menu

Anti-FGFR3 Monoclonal Antibody B-701

Known as: B-701 
A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the fibroblast growth factor receptor type 3 (FGFR3), with potential… 
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PD47-08 FIERCE-21: PHASE 2 STUDY OF VOFATMAB (B-701), A SELECTIVE INHIBITOR OF FGFR3, AS SALVAGE THERAPY IN METASTATIC UROTHELIAL CARCINOMA (MUCC)
INTRODUCTION AND OBJECTIVES: Patients (pts) with mUC who have failed platinum-based chemotherapy have a poor prognosis. About 20… 
2019
2019
FIERCE-21: Phase 2 study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUCC)
2017
2017
Safety and efficacy of docetaxel + b-701, a selective inhibitor of FGFR3, in subjects with advanced or metastatic urothelial carcinoma.
4540Background: Patients w/ locally advanced or metastatic urothelial carcinoma (UCC) have a poor prognosis. Prior to… 
2016
2016
B-701, a selective and potent inhibitor of fibroblast growth factor receptor 3 (FGFR3), may enhance the activity of bladder cancer therapies
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)